Versant Ventures, Sticking With its Knitting, Raises $950M for Early Stage Biotechs

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

What Happened in Switzerland?
RayzeBio Snags $45M to Reimagine Targeted Radiotherapies for Cancer
Graphite Bio Secures $45M Series A To Advance Targeted Gene Editing Therapy
Versant Ventures Wagers $35M on Cytokine Engineering with Bright Peak